ANSTO manufactures a range of radiopharmaceuticals that can be used as diagnostic and therapeutic agents. Labelled with radionuclides, these nuclear medicines can help medical practitioners to make an accurate diagnosis of an illness or to therapeutically treat diseased organs or tumours.
One such radiopharmaceutical is technetium-99 (tc-99m), the most widely-used radioisotope in nuclear medicine which decays from its parent radioisotope, molybdenum-99 (mo-99). Mo-99 is produced in the OPAL reactor and delivered to practitioners within ANSTO manufactured shielded Gentech® Generators.
For more information on radioisotopes and medical uses visit: What are radioisotopes?
ANSTO produces a range of radiochemicals to support research, industry and the manufacture of radiopharmaceuticals.